Abstract

Eli Lilly will report its quarterly results on August 05, 2026 Pre-Market; this preview compiles last quarter’s performance, the latest company and market forecasts, and consensus analyst views within the January 01, 2026 to July 29, 2026 window.

Market Forecast

Based on the company’s current-quarter forecast set, total revenue is estimated at 20.71 billion US dollars, up 40.78% year over year; EBIT is estimated at 7.27 billion US dollars, up 17.24%; and EPS is estimated at 6.01, up 10.08% year over year. Forecast commentary does not explicitly provide gross margin or net profit margin; however, the latest quarterly gross margin base was 81.93% and net profit margin was 37.36%, which investors will benchmark when parsing this quarter’s results. Management attention centers on the growth engine in obesity and diabetes incretin therapies, while pipeline launches are expected to shape the medium-term mix. The product with the largest incremental potential centers on tirzepatide franchise demand expansions in both diabetes and obesity, with last quarter revenue of 8.66 billion US dollars and rapid year-over-year growth momentum.

Last Quarter Review

Eli Lilly posted revenue of 19.80 billion US dollars, a gross margin of 81.93%, GAAP net profit attributable to shareholders of 7.40 billion US dollars, a net profit margin of 37.36%, and adjusted EPS of 8.55, with year-over-year growth of 55.55% for revenue and 155.99% for adjusted EPS. Quarter-on-quarter net profit growth was 11.42%. A notable highlight was broad-based beat versus estimates across revenue and profitability, with EBIT at 9.32 billion US dollars above the prior consensus. The main business mix was led by the tirzepatide franchise at 8.66 billion US dollars, followed by Zepbound at 4.16 billion US dollars, with multiple early-launch assets contributing smaller but rising revenue bases.

Current Quarter Outlook

Main commercial engine: Incretin therapies scale, supply, and pricing dynamics

This quarter’s narrative will be defined by the incretin portfolio’s volume trajectory and fulfillment rates across tirzepatide in type 2 diabetes and obesity. With a prior-quarter gross margin of 81.93%, investors will parse whether manufacturing scale and mix effects sustain a similar level as higher-margin obesity indications expand. Pricing and payer dynamics in the United States remain a swing factor; any broadening of coverage, especially in employer and commercial channels, can convert waiting lists into realized prescription volumes. International uptake continues to widen, but near-term capacity and fill-finish steps determine how much demand converts into recognized revenue in the quarter.

Most promising growth vector: Expanding tirzepatide addressable market

The tirzepatide franchise, at 8.66 billion US dollars last quarter, remains the primary growth vector as indications broaden and global launches accelerate. Year-over-year growth expectations embedded in the consolidated revenue forecast imply sustained double-digit expansion for the franchise, supported by step-ups in manufacturing throughput and geographic breadth. Key near-term watch items are prescription growth rates, inventory normalization at wholesalers, and any commentary on dose availability; these will inform whether revenue momentum can maintain the forecasted trajectory.

Stock-price drivers: Launch execution, capacity updates, and operating leverage

Equity reaction is likely to hinge on the combination of revenue growth versus consensus, guidance cadence for the back half of the year, and visibility on supply unlocks. Positive inflections in capacity additions typically translate into outsized volume gains in high-demand doses, supporting both topline and operating leverage. On the cost side, commercialization investments behind new launches and late-stage R&D can modestly pressure margins, but the sheer revenue scale from incretins is positioned to offset the step-up if volumes track to plan.

Analyst Opinions

Bullish opinions dominate recent commentary, with buy/overweight views outnumbering neutral or negative takes by a sizable margin. Several well-followed brokers highlight sustained upside risk to revenue from incretin demand and manufacturing scale-up, while noting that consensus already embeds robust growth. The prevailing stance anticipates a constructive print driven by above-trend obesity uptake and continued diabetes share gains, with valuation sensitivity tied to the quality of supply updates and the EPS flow-through. Overall, the majority view expects Eli Lilly to meet or exceed its revenue and EPS forecasts for the quarter and to maintain a confident outlook tied to capacity expansion and pipeline execution.